CN101784277A - 儿科肿瘤的治疗 - Google Patents

儿科肿瘤的治疗 Download PDF

Info

Publication number
CN101784277A
CN101784277A CN200880101385A CN200880101385A CN101784277A CN 101784277 A CN101784277 A CN 101784277A CN 200880101385 A CN200880101385 A CN 200880101385A CN 200880101385 A CN200880101385 A CN 200880101385A CN 101784277 A CN101784277 A CN 101784277A
Authority
CN
China
Prior art keywords
tumor
pediatric
treatment
tumors
pnet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880101385A
Other languages
English (en)
Chinese (zh)
Inventor
C·皮萨诺
L·维西
P·卡米纳蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101784277A publication Critical patent/CN101784277A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880101385A 2007-08-01 2008-07-03 儿科肿瘤的治疗 Pending CN101784277A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07113603 2007-08-01
EP07113603.0 2007-08-01
PCT/EP2008/058601 WO2009015981A2 (en) 2007-08-01 2008-07-03 Treatment of pediatric tumors

Publications (1)

Publication Number Publication Date
CN101784277A true CN101784277A (zh) 2010-07-21

Family

ID=38799381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880101385A Pending CN101784277A (zh) 2007-08-01 2008-07-03 儿科肿瘤的治疗

Country Status (11)

Country Link
US (1) US8829021B2 (https=)
EP (1) EP2182951A2 (https=)
JP (2) JP5765937B2 (https=)
KR (1) KR20100051837A (https=)
CN (1) CN101784277A (https=)
BR (1) BRPI0815051A2 (https=)
CA (1) CA2694389C (https=)
EA (1) EA015933B1 (https=)
MX (1) MX2010001084A (https=)
SG (1) SG183010A1 (https=)
WO (1) WO2009015981A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015195120A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
KR20260033630A (ko) 2015-10-30 2026-03-10 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
PT1962850E (pt) * 2005-12-21 2012-05-21 Sigma Tau Ind Farmaceuti Tratamento de tumores resistentes a drogas
EP2120948A1 (en) * 2007-02-13 2009-11-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Also Published As

Publication number Publication date
MX2010001084A (es) 2010-03-25
JP2014111653A (ja) 2014-06-19
EA015933B1 (ru) 2011-12-30
EA201070193A1 (ru) 2010-06-30
EP2182951A2 (en) 2010-05-12
CA2694389A1 (en) 2009-02-05
WO2009015981A3 (en) 2009-09-03
US8829021B2 (en) 2014-09-09
KR20100051837A (ko) 2010-05-18
CA2694389C (en) 2016-01-19
JP2010534699A (ja) 2010-11-11
WO2009015981A2 (en) 2009-02-05
JP5765937B2 (ja) 2015-08-19
AU2008282024A1 (en) 2009-02-05
SG183010A1 (en) 2012-08-30
BRPI0815051A2 (pt) 2015-02-10
US20100197718A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
CN104363913B (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CN114641293B (zh) 一种fgfr抑制剂的用途
ES2993492T3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
JP2020158507A (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
US20130324570A1 (en) Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics
BR112017010188B1 (pt) Análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer
CN114366743A (zh) 具有驱动致癌突变的癌症的治疗
CN101784277A (zh) 儿科肿瘤的治疗
US20230277522A9 (en) Methods for treating vascular malformations
JP2012012305A (ja) 抗がん剤の作用増強剤
TWI891650B (zh) 治療血管畸形之方法
CN111132672A (zh) 抗药性胶质瘤的治疗
AU2008282024B2 (en) Treatment of pediatric tumors
WO2016183915A1 (zh) A674563在携带flt3突变型基因的急性白血病中的新用途
WO2008086008A1 (en) Method of treating multidrug resistant cancers
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
HK1142810A (en) Treatment of pediatric tumors
US20100048603A1 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
WO2020120656A1 (en) Treatment and prevention of glioblastoma
Ramachandran Repurposing pimavanserin, an antipsychotic drug for pancreatic cancer and medulloblastoma treatment
HK40106737A (zh) 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂
HK40097577A (zh) 对parp抑制剂耐药的癌症的治疗剂
WO2023008511A1 (ja) Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤
BR112018006498B1 (pt) Composto, uso do mesmo e composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142810

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100721

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142810

Country of ref document: HK